Document:

Research Agreement

 Exhibit 10.17 

***Text Omitted and Filed Separately 

with the Securities and Exchange Commission. 

Confidential Treatment Requested 

Under 17 C.F.R. Sections 200.80(b)(4) 

and Rule 406 of the Securities 

Act of 1933, as amended. 

RESEARCH AGREEMENT 

HDTRA1-10-C-0004 

THIS RESEARCH AGREEMENT (“Agreement”) is made by and
between TRIUS THERAPEUTICS, INC. (“Sponsor”) with offices at 6310 Nancy Ridge Drive, Suite 101, San Diego, CA 92121, and THE REGENTS
OF THE UNIVERSITY OF CALIFORNIA, a California Corporation having its principal office at 1111 Franklin Street,
5th floor, Oakland, California 94607-5200, on behalf of
Scripps Institution of Oceanography at the University of California, San Diego campus (“University”) located at 9500 Gilman Drive, La Jolla, California 92093-0210. 

WHEREAS, it is in the mutual interest of Sponsor and University that research be conducted on a project entitled
“Broad Spectrum Antibacterial Therapeutics from Marine Products” (the “Project”); 

WHEREAS, Sponsor desires to financially support said research at University; 

NOW, THEREFORE, the parties agree as follows: 

1. SCHEDULE. The Project shall be conducted in accordance with the Statement of Work attached hereto as Exhibit A (the
“Statement of Work”) and incorporated into this Agreement by this reference. The Project shall be carried out during the Project Period specified in the Statement of Work, namely April 21, 2010 through September 20,
2014 unless sooner terminated as herein provided. 
 2. BUDGET. The funding for Sponsor’s support of the Project is provided through
contract HDTRA1-10-C-0004 between Sponsor and the Defense Threat Reduction Agency (the “DTRA Contract”). This Agreement is a subcontract under the DTRA Contract and therefore the terms and conditions of the DTRA Contract that
are applicable to University as a subcontractor are attached hereto as Exhibit B (“DTRA Requirements”) and deemed incorporated into and made a part of this Agreement. The total estimated cost of the Project is
$4,306,007 covering the period April 21, 2010 through September 20, 2014. The Agreement is incrementally funded with [...***...] currently available for payment covering the period [...***...] through [...***...]. Under this
Agreement the University shall cover all direct and indirect costs of the Project as set forth in the budget attached hereto in Exhibit C (the “Budget”). University shall use its reasonable efforts to ensure that the
cost of the Project remains within such Budget. The Budget attached hereto as Exhibit C includes Sponsor’s entire payment obligation under this Agreement for University’s performance of the Project. In no event will Sponsor be
obligated to pay to University amounts in excess of the Budget without Sponsor’s prior written consent. If at any time University has reason to believe that 

 

 ***Confidential Treatment Requested 

 
the cost of the Project will be greater than the amount in the Budget, University shall notify Sponsor in writing to that effect, giving a revised budget of the cost of completion of the Project.
Sponsor shall not be obligated to reimburse University for the costs incurred in excess of the Budget unless and until Sponsor has notified University in writing that the revised budget is accepted. Upon expenditure of the accepted budget amount in
accordance with the Budget, University’s obligation to continue performance of the Project shall cease. If the Project period is [...***...], the balance of any funds remaining at the end of any Project year can be carried over to
subsequent years during the period of the Agreement to support the Project. In addition, if the DTRA Contract is terminated, University shall use its best efforts to cease any further Project activities upon receipt of written notice thereof from
Sponsor. 
 3. PAYMENT. University will submit invoices to Sponsor monthly for actual work performed under the Statement of Work and
Sponsor shall remit payment of all undisputed amounts within [...***...] of receipt of invoice. 
 Payment shall be made
to “The Regents of the University of California” and sent to the following: 
 The Regents of the University of
California 
 University of California-San Diego 

Office of Post Award Financial Services 

ATTN: Connie Mulock 

9500 Gilman Drive 

La Jolla, CA 92093-0954 
 Or
paid by wire transfer to: 
 [...***...] 

Addendum information to be included: 

Principal Investigator’s name: 

Invoice Number being paid 

Exact amount of incoming funds 
  

 ***Confidential Treatment Requested 

2. 

 The University shall mail the invoice to: 

Trius Therapeutics, Inc. 

Attention: Accounts Payable 

6310 Nancy Ridge Drive, Suite 101 

San Diego, CA 92121 
 4.
PRINCIPAL INVESTIGATOR. The Project is to be conducted by University under the direction of William Fenical (“Principal Investigator”) with the participation of other research personnel of University under
Principal Investigator’s immediate and direct control during the performance of the Project. Principal Investigator will be responsible for the direction of the Project, including all budgeting and revisions to the Budget, in accordance with
applicable University policies. 
 5. CONFIDENTIALITY. Subject to Paragraph 9 of this Agreement, it is the intent of the parties
that neither party shall furnish any information considered confidential and/or proprietary by it and/or one or more third parties to the other party in connection with this Agreement except as expressly set forth herein. 

During the term of this Agreement and for a period of [...***...] thereafter, University and Principal Investigator will
maintain all Confidential Information of Sponsor as confidential and will not disclose any Confidential Information of Sponsor or use any Confidential Information of Sponsor for any purpose, except (i) as expressly authorized by this Agreement, (ii)
as required by law, rule, regulation or court order (provided that University uses reasonable efforts to obtain a protective order or to seek confidential treatment of any such information required to be disclosed), or (iii) to its employees,
agents, consultants, independent contractors, affiliates and other representatives who require access to such information to accomplish the purposes of this Agreement so long as such persons are under obligations of confidentiality, non-disclosure,
and non-use no less stringent than as set forth herein. University agrees to use at least the same standard of care as it uses to protect its own Confidential Information (which in no case will be less than reasonable standard of care) to ensure
that its employees, agents, consultants and other representatives do not disclose or make any unauthorized use of the Confidential Information. University and Principal Investigator will promptly notify Sponsor upon discovery of any unauthorized use
or disclosure of Confidential Information. For purpose of this Agreement, should 
  

 ***Confidential Treatment Requested 

3. 

 
Sponsor deem it necessary to disclose information considered confidential and/or proprietary by it to University, it will be clearly marked by Sponsor, in writing, as “Confidential
Information.” Proprietary/confidential information shall also include oral disclosures provided that the oral disclosure is reduced to writing in summary form, marked as “Confidential Information,” and delivered to the Receiving Party
within [...***...] of oral disclosure. This obligation does not apply to information that was known to University prior to its receipt from Sponsor as evidenced by its competent written records, that is independently developed by
University without reference to or use of such information, or that enters the public domain through no fault of University. 
 6. RIGHTS IN
DATA. Subject to Paragraph 5, 8 and 9 of this Agreement, University shall have the right to publish, disclose, disseminate and use, in whole and in part, any data and information received or developed under this Agreement. Subject to the terms
of the Publication, and Disclosure and Patent Rights provisions of this agreement, Sponsor shall have the right to disclose, publish and use the technical reports, data and information delivered hereunder to Sponsor by University. 

7. USE OF NAME/PUBLICITY. It is agreed by each party that it will not under any circumstance use the name of the other party or its employees in
any advertisement, press release or publicity with reference to this Agreement, without prior, written approval of the other party. 
 8.
PUBLICATION. Subject to the limitations set forth in this Paragraph 8 and elsewhere in the Agreement as well as in the DTRA Requirements, University shall have the right to publish or present the results of the work conducted by University under
this Agreement provided that (a) such publications do not contain Confidential Information of Sponsor and (b) the information proposed to be published results from “Fundamental research,” meaning basic and applied research in science and
engineering, the results of which ordinarily are published and shared broadly within the scientific community, as distinguished from proprietary research and from industrial development, design, production, and product utilization, the results of
which ordinarily are restricted by the U.S. Government for proprietary or national security reasons (referred to herein as “Government-sensitive information”) and provided further that University shall provide Sponsor with a
copy of any proposed manuscripts describing said work [...***...] prior to submission for publication in order to allow Sponsor and authorized DTRA representatives to review such manuscripts for disclosure of Confidential Information of
Sponsor or for potentially patentable Inventions and in order for Sponsor to comply with its obligations under the DTRA Contract. Sponsor and/or authorized DTRA representatives will have the right (a) to propose modifications to the publication for
protection of Confidential Information of Sponsor or 
  

 ***Confidential Treatment Requested 

4. 

 
Government-sensitive information, and (b) to request a delay in publication in order to protect patentable information. If Sponsor requests such a delay, University will delay submission of
the publication for a period of [...***...] to enable patent applications protecting Sponsor’s rights in such information to be filed. Upon the expiration of [...***...] from delivery of the proposed written publication to
Sponsor, University will be free to proceed with the written publication unless Sponsor has requested the delay described above. In no event shall University publish or present any Confidential Information of Sponsor without Sponsor’s prior
written consent. If, at any time during the review of University’s proposed publication(s) it is determined that information would be considered sensitive or inappropriate for release to the public, University shall in good faith consider any
modifications suggested by Sponsor and the Government. 
 University and/or its employees, agents, consultants or other
representatives (including Principal Investigator) shall where scientifically appropriate give appropriate credit to Sponsor and its employees in any such publication or presentation. University shall also acknowledge the support of the U.S.
Government as required under the DTRA Requirements by DFAR Clause 252.235-7010. 
 9. DISCLOSURE AND PATENT RIGHTS. Subject to any
applicable rights the U.S. Government may have under the DTRA Contract, title to inventions, developments or discoveries, including software, arising from the Project (“Inventions”) shall be determined in accordance with
inventorship as determined under United States patent Law Title 35, United States Code. University shall promptly disclose to Sponsor in writing each University Invention and Joint Invention in sufficient detail to allow Sponsor to appreciate the
significance of such Invention. 
 (a) Sponsor Inventions. Subject to any applicable rights the U.S. Government may have under the DTRA
Contract, all rights to Inventions made solely by Sponsor (“Sponsor Inventions”) shall belong solely to Sponsor. 

(b) University Inventions. Subject to any applicable rights the U.S. Government may have under the DTRA Contract, all rights to
Inventions made solely by University (“University Inventions”) shall belong solely to University and shall be disposed of in accordance with this Paragraph 9 and University policy. Sponsor shall be entitled to a
non-exclusive, non-commercial, non-transferable, royalty-free license to use any such University Inventions for Sponsor’s internal, non-commercial research purposes only. 

(c) Joint Inventions. Subject to any applicable rights the U.S. Government may have under the DTRA Contract, all rights to Inventions made jointly
by University and Sponsor (“Joint Inventions”) shall be jointly-owned by University and Sponsor. 
  

 ***Confidential Treatment Requested 

5. 

 (d) Option for License. To the extent University has the legal right to do so and
subject to any applicable rights of the U.S. Government, University hereby also grants to Sponsor, in accordance with the provisions of the following paragraph, an exclusive, time limited, first right to negotiate a commercial, exclusive (or
non-exclusive at Sponsor’s option), worldwide, irrevocable, fully sub-licensable, royalty- bearing license under University’s interest in any Invention, to make, have made, use, sell, offer for sale, have sold and import any such Invention
conceived and first actually reduced to practice in the performance of the Project under this Agreement, for the term of any patent thereon. Sponsor shall hold any such disclosure regarding a University Invention on a confidential basis and will not
disclose such information to any third party without consent of University. Sponsor shall advise University in writing within [...***...] of disclosure, which period may be extended upon mutual consent of both Parties of any such
University Invention or Joint Invention to Sponsor (the “Option Period”) whether or not it wishes to secure a commercial license. [...***...] Sponsor shall have [...***...] from the date of election to conclude a
license or option agreement with University, which period may be extended by mutual agreement. Both parties agree to negotiate in good faith during such negotiation period. Such definitive license agreement shall contain reasonable terms and
[...***...]. University agrees that, during the Option Period for a University Invention or Joint Invention and during any license negotiations with Sponsor arising therefrom, it shall not offer to any third party the opportunity to
obtain a license, or enter into any license with any third party, with respect to such University Invention or University’s rights in such Joint Invention (as applicable), unless Sponsor expressly rejects in writing its exclusive negotiation
rights set forth herein. If Sponsor elects not to secure such license(s), or such license has not been concluded within the [...***...] period described above, University’s rights to the Invention(s) disclosed hereunder shall be disposed
of in accordance with University policies, with no further obligation to Sponsor (it being understood that Sponsor shall continue to have its joint ownership interest in any Joint Invention and shall be free to practice any Joint Invention without
the consent of, or any obligation to account to, University). Notwithstanding any failure of the parties to agree on license terms, University shall not grant any license with respect to a University Invention or Joint Invention to any third party
[...***...] 
  

 ***Confidential Treatment Requested 

6. 

 
[...***...]. Sponsor may exercise its right to obtain a license with respect to any single University Invention or Joint Invention disclosed to Sponsor pursuant to this Paragraph 9,
and any failure by Sponsor to exercise its right to obtain a license with respect to any single University Invention or Joint Invention shall not be deemed a waiver of Sponsor’s right to obtain a license with respect to any other University
Invention or Joint Invention disclosed to Sponsor hereunder. 
 (e) Patent Prosecution. University may, at its discretion, file an
application for, and take steps to obtain and maintain the validity of a patent(s) related to a University Invention, in the United States and/or any other country, and/or may take any other action (such as Copyright registration) to obtain other
protection for a University Invention in any country. If University declines to apply for and/or to maintain patent and/or any other intellectual property protection in the United States and/or any other country for any University Invention to which
Sponsor has an active licensing option or license, University shall provide reasonable prior written notice to Sponsor of such intention to not apply for or to abandon any such patent or intellectual property protection (which notice shall, in any
event, be given no later than [...***...] prior to the next deadline for any action that may be taken with respect to such patent application with the U.S. Patent & Trademark Office or any foreign patent office) and Sponsor shall have
the right, at is expense, to prepare, file, prosecute, and maintain such patent application in University’s name in any country. 
 10.
DECLARATIONS AND CERTIFICATIONS. As required by the DTRA Requirements, University hereby declares and certifies that: 
  

	 	(i)	To the best of its knowledge and belief, no Federal appropriated funds have been paid or will be paid to any person for influencing or attempting to influence an
officer or employee of any agency, a member of Congress, an officer or employee of Congress, or an employee of a member of Congress on its behalf in connection with the awarding of this Agreement; 

 

	 	(ii)	As of the signing of this Agreement, University and its employees are not debarred, suspended, or proposed for debarment from the Federal Government and are not
ineligible for the award of Defense contracts or subcontracts because of it or their inclusion in the web-based Excluded Parties List System operated by the General Services Administration and University further declares and certifies that it has
knowledge of the Excluded Parties List System and has policies and procedures in place for confirming its con tractors against this list; 

  

 ***Confidential Treatment Requested 

7. 

	 	(iii)	To the best of its knowledge and belief, the cost and pricing data contained in the Budget and submitted to Sponsor is accurate, complete, and current as of the
date of this Agreement; and 

  

	 	(iv)	To the best of its knowledge and belief, University and its employees have not been convicted of fraud or any other felony arising out of a contract with the
Department of Defense. 

 11. INDEMNIFICATION. Sponsor agrees to defend, indemnify and hold University harmless from and
against any and all liability, loss, expense, reasonable attorneys’ fees, or claims for injury or damages arising out of third party claims resulting from the performance of this Agreement, but only in proportion to and to the extent such
liability, loss, expense, attorneys’ fees, or claims for injury or damages are caused by or result from the negligent or intentional acts or omissions of Sponsor, its officers, agents or employees. 

University agrees to defend, indemnify and hold Sponsor harmless from and against any and all liability, loss, expense, reasonable
attorneys’ fees, or claims for injury or damages arising out of third party claims resulting from the performance of this Agreement, but only in proportion to and to the extent such liability, loss, expense, attorneys’ fees, or claims for
injury or damages are caused by or result from the negligent or intentional acts or omissions of University, its officers, agents, or employees. 

Each party’s agreement to indemnify, defend and hold the other party and its respective indemnitees harmless is conditioned upon the
indemnified party: (a) providing prompt written notice to the indemnifying party of any claim, demand or action arising out of the indemnified activities; (b) permitting the indemnifying party to assume full responsibility and authority to
investigate, prepare for and defend against any such claim or demand; (c) reasonably assisting the indemnifying party, at the indemnifying party’s reasonable expense, in the investigation of, preparation for and defense of any such claim
or demand; and (d) not compromising or settling such claim or demand without the indemnifying party’s written consent. 
 12.
EQUIPMENT. In the event that University purchases equipment hereunder, title to such equipment shall will remain government property as required under the DTRA Contract by Federal Acquisition Regulation Clause 52.245-1. 

13. EXCUSABLE DELAYS. In the event of a delay caused by inclement weather, fire, flood, strike or other labor dispute, act of God, act of
governmental officials or agencies, or any other cause beyond the control of a party, such party shall be excused from performance hereunder for the period of time attributable to such 

 

 ***Confidential Treatment Requested 

8. 

 
delay, which may extend beyond the time lost due to one or more of the causes mentioned above. In the event of any such delay, this Agreement may be revised by changing the Budget, performance
period and other provisions, as appropriate, by mutual agreement of the parties. 
 14. NOTICE. Whenever any notice is to be given
hereunder, it shall be in writing and sent to the following address: 
  

			
	University:	 	Nancy Wilson
	 (U.S. Mail)
	 	Office of Contract and Grant Administration
		 	Scripps Institution of Oceanography
		 	University of California, San Diego
		 	9500 Gilman Drive
		 	La Jolla, California 92093-0210
		
	 for courier delivery:
	 	Nancy Wilson
		 	Office of Contract and Grant Administration
		 	Scripps Institution of Oceanography
		 	116 Scripps Building
		 	8622 Charles F. Kennel Way (formerly Discovery Way)
		 	La Jolla, California 92037
		
	 Sponsor:
	 	Trius Therapeutics, Inc.
		 	c/o Jeff Stein, CEO
		 	6310 Nancy Ridge Drive, Suite 101
		 	San Diego, CA 92121

 15. TERMINATION. This
Agreement maybe terminated by Sponsor at any time upon the giving of thirty (30) days prior written notice to University and by University at any time upon the giving of ninety (90) days prior written notice to Sponsor. Written notice
shall be directed to the appropriate individual named in Paragraph 14 (“NOTICE”) of this Agreement. In addition, Sponsor shall have the right to terminate this Agreement immediately upon written notice to University if the
DTRA Contract is terminated. Upon the giving of notice of termination by the Sponsor, University shall exert its best efforts to limit or terminate any outstanding commitments. Sponsor shall reimburse University for all documented costs incurred by
it for all work performed through the effective termination date, and for all outstanding obligations which cannot be canceled. Such obligations may include [...***...] 

 

 ***Confidential Treatment Requested 

9. 

 
[...***...]. In addition, University shall also be reimbursed for additional costs which may be incurred as a result of termination, including [...***...]. University shall
furnish, within [...***...] of the effective date of termination, a final statement describing in detail: (i) all costs to be reimbursed pursuant to the terms of this Paragraph 15 and (ii) a final summary of all funds expended. Upon
the giving of notice of termination by University, as of the effective termination date Sponsor shall have no additional liability for any costs or obligations. In addition, University shall furnish, within [...***...] of the effective date of
termination, a final summary of all funds expended and shall reimburse Sponsor for any funds paid by Sponsor to University in excess of total funds expended by University. Termination or expiration of this Agreement shall not affect the rights and
obligations of the parties that accrued prior to the effective date of such termination or expiration. The provisions of Paragraphs 5, 6, 7, 8, 9, 11, 14, 15 and 16 shall survive termination or expiration of this Agreement. 

16. MISCELLANEOUS. Neither party may assign this Agreement without the prior written consent of the other party, such consent not to be
unreasonably withheld; provided, however, that Sponsor may assign this Agreement without such consent to an affiliate of Sponsor or in connection with the transfer or sale of all or substantially all of Sponsor’s business to which this
Agreement relates to a third party, whether by merger, sale of stock, sale of assets or otherwise. If any provision of this Agreement becomes or is declared illegal, invalid or unenforceable, such provision will be separable from this Agreement and
the remaining provisions shall continue in full force and effect. If such separation substantially alters the basis of this Agreement, the parties shall negotiate in good faith to amend the provisions of this Agreement to give effect to the original
intent of the parties. University and Sponsor are independent contractors, and neither is an agent, joint venturer or partner of the other. This Agreement and all obligations arising hereunder shall be governed by the laws of the State of California
without regard to any choice of law provisions thereof that would cause the application of the laws of a different jurisdiction. This Agreement, together with the Exhibits hereto, represents the entire agreement and understanding between the parties
with respect to its subject matter and supersedes any prior and/or contemporaneous discussions, representations or agreements, whether written or oral, of the parties regarding the subject matter hereof. In the event of a conflict between the terms
of the Statement of Work and the terms of this Agreement, the provisions of this Agreement shall govern. In the event of a conflict between the terms of this Agreement and the terms of the DTRA Requirements, the provisions of the DTRA Requirements
shall govern. Amendments or changes to this Agreement shall be valid and binding only if in writing and signed by duly authorized representatives of the parties. No provision of this Agreement can be waived except by the express written consent of
the party waiving compliance. Except as specifically provided for herein, the waiver from time to time by either party of any of its rights or its failure 

 

 ***Confidential Treatment Requested 

10. 

 
to exercise any remedy shall not operate or be construed as a continuing waiver of some or of any other or such party’s rights or remedies provided in this Agreement. This Agreement may be
executed in two counterparts, which shall together constitute the same legal instrument. 
  

									
	 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
	 		 	TRIUS THERAPEUTICS, INC.
					
	By:	 	 /s/ Nancy A.F. Wilson
	 		 	By:	 	 /s/ Jeff Stein

	Name:	 	Nancy A.F. Wilson	 		 	Name:	 	Jeff Stein
	Title:	 	 Director, Office of Contract

and Grant Administration, SIO
	 		 	Title:	 	CEO
					
	Date:	 	5/13/10	 		 	Date:	 	5/13/10

 The undersigned Principal investigator hereby
acknowledges receipt of a complete copy of this Agreement. 
  

			
	By:	 	 /s/ William Fenical

	Name:	 	William Fenical

  

 11. 

 EXHIBIT A 

Statement of Work 

(See Attached) 

Broad Spectrum Antibacterial Therapeutics from Marine Natural Products 

TMTI-DRUG-02: Trius Therapeutics 

Statement of Work 
 1.0 –
Objective: The goal of this program is to develop a safe, potent antimicrobial agent derived from marine sediment actinomycete fermentations. The agent will have a novel, bacterial-specific mechanism of action for the prophylaxis and treatment
of infectious diseases caused by Category A and B bacterial pathogens. We will maximize the opportunity for rapid progress by collecting and fermenting novel actinomycetes from a novel resource, marine sediments. We will minimize the time for
discovery of novel mechanism antibacterials using our unique collection of Bacillus anthracis antisense strains hypersensitized to [...***...] different bacterial-specific essential targets. We will accelerate development of
therapeutics from these discoveries using our structural biology platform to co-crystallize the natural products with the protein targets, thus allowing semi-synthetic modification to optimize the drug properties. [...***...] The resulting
therapeutics will show no cross-resistance to existing drugs and a broad pathogen spectrum. Thus, we mitigate the defense threat and aid the warfighter by providing a unique, cost-effective solution to counter multiple possible bacterial biowarfare
agents with a single therapeutic agent. 
 2.0 – Scope: This proposal to develop therapeutic countermeasures against Category A and
B bacterial pathogens is in support of the Defense Threat Reduction Agency (DTRA) Chemical and Biological Defense Medical S&T Division research and development program. The scope of work for this contract falls into the following 4 stages:
[...***...] Time frames are shown below with more details of the Base period, Option Periods and Option Tasks outlined in Attachment 1. 

In Option Task 1, [...***...] 

It is anticipated that[...***...]. However, the other studies in Option 3 are budgeted for a single compound. DTRA
[...***...] and [...***...] to be triggered at the discretion of DTRA (see figure below). 
  

 ***Confidential Treatment Requested 

12. 

 [Period of Contract and Budget 

[...***...] 
 3.0 –
Background: 
 Bioweapons derived from bacterial pathogens are a serious and present danger to the warfighter. The nature of these bacterial
bioweapons will require therapeutics with novel mechanisms of action because of the likelihood that such bioweapons will be engineered for resistance against known therapeutics. New antibacterial therapeutics to address this danger are not currently
in development. The reality of the danger combined with the paucity of new therapeutics creates a strong urgency for a rapid process with a high likelihood of success. Bacteria of the subgroup Actinomycetales have been the most prolific
source of new antibiotics, providing more than 80% of the antibiotic drugs in use today. The method of discovering antibacterials from soil-derived actinomycetes is well established and includes fermenting the bacteria to elicit production of
secondary metabolites, extraction of the resulting broth and then testing for antibacterial activity. Because of the long effort by countless numbers of researchers examining terrestrial soil, it is increasingly difficult to find novel
antibacterials from this source with properties useful in addressing the biowarfare pathogens contemplated here. 
 While the
search for antimicrobials from the soil-based milieu has reached a point of diminishing returns, recent advances in marine microbiology have opened unprecedented opportunities for the discovery of useful new antibiotics from ocean sediment
microorganisms. [...***...] 
  

 ***Confidential Treatment Requested 

13. 

 
[...***...]. 
 The Base period milestone is
[...***...] The goal of Option Period 1 is [...***...] Option 2 (preclinical), where[...***...]. Up to [...***...]. 

4.0 – Tasks/ Technical Requirements: 

BASE PERIOD 1 (18 months): [...***...] 
  

	 	4.0	The contractor should [...***...]. 

The contractor shall submit the [...***...] 

Option Task 4.1: [...***...] 
  

	 	4.1	The contractor shall [...***...]. 

  

	 	4.2	The contractor shall [...***...]. 

  

	 	4.3	The contractor shall [...***...] 

GOAL: [...***...] 

BASE PERIOD INTERIM MILESTONE [...***...]: The contractor should [...***...]. 

 

 ***Confidential Treatment Requested 

14. 

 BASE PERIOD INTERIM MILESTONE [...***...]: The contractor should
[...***...] 
  

					
	 4.4
	 	The contractor should [...***...].
			
		 	 4.4.1
	  	The contractor should [...***...]
			
		 	 4.4.2
	  	The contractor should [...***...]
			
		 	 4.4.3
	  	The contractor should [...***...]
			
		 	 4.4.4
	  	The contractor should [...***...]
		
	 4.5
	 	 The contractor should characterize the activity of the isolated components
[...***...]

		
	 4.6.
	 	 The contractor should [...***...]

BASE PERIOD MILESTONE [...***...] 
  

 ***Confidential Treatment Requested 

15. 

 [...***...] 

OPTION PERIOD 1 [...***...]: 

[...***...] 
  

					
	 4.7.
	 	The contractor [...***...]
		
	 4.8.
	 	 The contractor should [...***...]

		
	 4.9.
	 	 The contractor should [...***...]

			
		 	 4.9.1
	 	The contractor should [...***...]
			
		 	 4.9.2
	 	The contractor should [...***...]

 OPTION
1 INTERIM MILESTONE: The contractor should [...***...]. 
 OPTION 1 INTERIM MILESTONE: The contractor should [...***...].

 OPTION 1 MILESTONE: The contractor should [...***...]. 

OPTION 1 MILESTONE: The contractor should [...***...] 

OPTION PERIOD 2 [...***...] 

[...***...] 
  

 ***Confidential Treatment Requested 

16. 

 [...***...]  

 

	 	4.10.	The contractor shall [...***...] 

OPTION PERIOD 2 MILESTONE: The contractor should [...***...]. 

OPTION PERIOD 2 MILESTONE: The contractor should [...***...] 

OPTION PERIOD [...***...] 

			
		
	 4.12.
	 	The contractor shall [...***...].
		
	 4.13.
	 	The contractor should [...***...]
		
	 4.14.
	 	The contractor shall [...***...]
		
	 4.15.
	 	The contractor shall complete [...***...]
		
	 4.16
	 	The contractor should [...***...].

  

 ***Confidential Treatment Requested 

17. 

 OPTION PERIOD 3 MILESTONE: [...***...] 

The contractor [...***...] 

OPTION PERIOD 3 [...***...] 

ALL BASE AND OPTION PERIODS 

FY1-FY5 
 Management 

 

			
	 4.19.
	  	The contractor shall
		  	[...***...]
		
	 4.21.
	  	The contractor shall [...***...]

 5.0
– CDRLs/Other deliverables: 
  

			
	 1.
	  	The contractor shall [...***...].

 

 ***Confidential Treatment Requested 

18. 

			
	 2.
	  	The contractor shall [...***...].
		
	3.	  	The contractor shall [...***...].
		
	4.	  	The contractor shall [...***...]
		
		  	    a.    The contractor shall [...***...].
		
		  	    b.    The contractor shall [...***...].
		
	5.	  	The contractor shall [...***...].
		
	6.	  	The contractor shall [...***...]
		
	7.	  	The contractor shall [...***...].
		
	8.	  	The contractor shall [...***...].
		
	9.	  	The contractor shall [...***...].
		
	10.	  	The contractor shall [...***...].

Attachment 1: SUMMARY OF TASKS/TECHNICAL REQUIREMENTS 

 

 ***Confidential Treatment Requested 

19. 

 [...***...] 

 

 ***Confidential Treatment Requested 

20. 

 [...***...] 

 

 ***Confidential Treatment Requested 

21. 

 Attachment 2: CONTRACT DATA REQUIREMENTS LIST 

 

																											
	
CONTRACT DATA REQUIREMENTS LIST

(2 Data Items)
	  	 Form Approved

 OMB No. 0704-0188
	 	 	  		 	
	  

The public reporting burden for this collection of information is estimated to average 220 hours per response, including the time for reviewing
instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information,
including suggestions for reducing the burden, to the Department of Defense, Executive Services Directorate (0704-0188). Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for
failing to comply with a collection of information if it does not display a currently valid OMB control number. Please do not return your form to the above organization. Send completed form to the Government Issuing Contracting Officer for the
Contract/PR No. listed in Block E.
  
	 	 	  		 	
	 A.
CONTRACT LINE ITEM NO.
 NA
	  	 B. EXHIBIT

A
	  	 C. CATEGORY:

    TDP                 TM  
             OTHER                        

	 	 	  		 	
	 D.
SYSTEM/ITEM
 Chemical/Biological Medical System
	  	E. CONTRACT/PR NO.	  	 F. CONTRACTOR

Trius Therapeutics
	 	 	  		 	
	 1. DATA ITEM NO.

A001
	  	 2. TITLE OF DATA ITEM

Work Breakdown Structure
	  	 3. SUBTITLE

3- Level Work Breakdown Structure
	 	 	  		 	17. PRICE GROUP
	 4. AUTHORITY (Data Acquisition
Document No.)
 DI-MGMT-81334C
	  	 5. CONTRACT REFERENCE

NA
	  	 6. REQUIRING OFFICE

DTRA/TMTI
	 	 	  		 	 
	 7. DD 250 REQ

LT
	  	 9. DIST STATEMENT
REQUIRED
  
 NA
	  	 10. FREQUENCY

See Blk 16
	  	 12.DATE OF FIRST
SUBMISSION
 See Blk 16
	  	
14.          DISTRIBUTION
	 	 	  		 	18. ESTIMATED
     TOTAL PRICE
	 8. APP
CODE
 A
	  	  	 11. AS OF DATE

See Blk 16
	  	 13.DATE OF SUBSEQUENT SUBMISSION

See Blk 16
	  	a. ADDRESSEE	  	b. COPIES	 	 	  		 	 
	  	  	  	  	  	Draft	  	Final	 	 	  		 	
	  	  	  	  	  	  	Reg	  	Repro	 	 	  		 	
	 16. REMARKS

 
 3-Level WBS with costs & schedule per each level. For lowest task level show
breakdown for labor, material and other indirect costs. Blk 10-13: First report due 15 days past award. Format provided to contractor. To be updated annually. Government review/approval is 15 days after receipt of first submittal. Provide changes to
draft within 10 days of such request. Provide final document within 10 days after approval of changes is received.
	  	DTRA/TMTI	  	 	  	1	  	 	 	 	  		 	
	  	DTRA/BCR	  	 	  	1	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	15. TOTAL    
è	  	0	  	2	  	0	 	 	  		 	
	 1. DATA ITEM NO.

A002
	  	 2. TITLE OF DATA ITEM

 Monthly Invoice Report
	  	 3. SUBTITLE

NA
	 	 	  		 	17. PRICE GROUP
	 4.
AUTHORITY (Data Acquisition Document No.)
 DI-MGMT-81334C
	  	 5. CONTRACT REFERENCE

NA
	  	 6. REQUIRING OFFICE

DTRA/TMTI
	 	 	  		 	 
	 7. DD 250 REQ

LT
	  	
9. DIST STATEMENT
REQUIRED

 
 NA
	  	 10. FREQUENCY

Monthly
	  	 12. DATE OF FIRST SUBMISSION

See BLK 16
	  	14. DISTRIBUTION	 	 	  		 	18. ESTIMATED
     TOTAL PRICE
	 8. APP
CODE
 A
	  	  	 11. AS OF DATE

See BLK 16
	  	 13. DATE OF SUBSEQUENT
SUBMISSION
 See BLK 16
	  	a. ADDRESSEE	  	b. COPIES	 	 	  		 	 
	  	  	  	  	  	Draft	  	Final	 	 	  		 	
	  	  	  	  	  	  	Reg	  	Repro	 	 	  		 	
	
16. REMARKS
  

Summary of invoices submitted during previous month or last month for which unreported data is available Format provided to contractor. Blk 11-13 Report
after first business day of the month after contract award and every month thereafter.
	  	DTRA/TMTI	  	 	  	1	  	 	 	 	  		 	
	  	DTRA/BCR	  	 	  	1	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	15. TOTAL    è	  	0	  	2	  	0	 	 	  		 	
	 G. PREPARED BY

 

	  	 H. DATE

 
 25 JUNE 09
	  	I. APPROVED BY	  	J. DATE	 	 	  		 	

					
	DD FORM 1423-2, AUG 96	  	PREVIOUS EDITION MAY BE USED.	  	                  Page        
of        Pages

  

 22. 

  

																											
	
CONTRACT DATA REQUIREMENTS LIST

(2 Data Items)
	  	 Form Approved

 OMB No. 0704-0188
	 	 	  		 	
	  

The public reporting burden for this collection of information is estimated to average 220 hours per response, including the time for reviewing
instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information,
including suggestions for reducing the burden, to the Department of Defense, Executive Services Directorate (0704-0188). Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for
failing to comply with a collection of information if it does not display a currently valid OMB control number. Please do not return your form to the above organization. Send completed form to the Government Issuing Contracting Officer for live
Contract/PR No. listed in Block E.
  
	 	 	  		 	
	 A.
CONTRACT LINE ITEM NO.
 NA
	  	 B. EXHIBIT

A
	  	 C. CATEGORY:

    TDP                 TM  
               OTHER                      

	 	 	  		 	
	 D.
SYSTEM/ITEM
     Chemical/Biological Medical System
	  	E. CONTRACT/PR NO.	  	 F. CONTRACTOR

Trius Therapeutics
	 	 	  		 	
	 1. DATA ITEM NO.

A003
	  	 2. TITLE OF DATA ITEM

Quarterly Status Report
	  	 3. SUBTITLE

Quarterly Contract Performance Report
	 	 	  		 	17. PRICE GROUP
	 4. AUTHORITY (Data Acquisition
Document No.)
 DI-ADMN-80447
	  	 5. CONTRACT REFERENCE

NA
	  	 6. REQUIRING OFFICE

DTRA/TMTI
	 	 	  		 	 
	 7. DD 250 REQ

LT
	  	 9. DIST STATEMENT
REQUIRED
  
 NA
	  	 10. FREQUENCY

Quarterly
	  	 12.DATE OF FIRST
SUBMISSION
 See Blk 16
	  	
14.          DISTRIBUTION
	 	 	  		 	
18.ESTIMATED

    TOTALPRICE

	  	  	  	  	 a. ADDRESSEE
	  	b. COPIES	 	 	  		 
	 8. APP
CODE
 A
	  	  	 11. AS OF DATE

See Blk 16
	  	 13.DATE OF SUBSEQUENT
SUBMISSION

See Blk 16
	  	  	 Draft
	  	 Final
	 	 	  		 
	  	  	  	  	  	  	 	 	  		 	
	  	  	  	  	  	  	Reg	  	Repro	 	 	  		 	
	 16. REMARKS

 
 Blks 11-13: First report due within 15 days after the end of the first Fiscal Quarter
post award. Subsequent reports due within 15 days of the end of each FQ. Format provided to the contractor. Government review/approval is 15 days after receipt of first submittal. Provide changes to draft within 10 days of such request. Provide
final document within 10 days after approval of changes is received.
	  	DTRA/TMTI	  	 	  	1	  	 	 	 	  		 	
	  	DTRA/BCR	  	 	  	1	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	15. TOTAL    
è	  	0	  	2	  	0	 	 	  		 	
	 1. DATA ITEM NO.

A004
	  	 2. TITLE OF DATA ITEM

 Quarterly Financial Status Report
	  	 3. SUBTITLE

NA
	 	 	  		 	17. PRICE GROUP
	 4.
AUTHORITY (Data Acquisition Document No.)
 DI-FNCL-80331A
	  	 5. CONTRACT REFERENCE

NA
	  	 6. REQUIRING OFFICE

DTRA/TMTI
	 	 	  		 	 
	 7. DD 250 REQ

LT
	  	
9. DIST STATEMENT
REQUIRED

 
 NA
	  	 10. FREQUENCY

Quarterly
	  	 12.DATE OF FIRST SUBMISSION

See Blk 16
	  	 14.          DISTRIBUTION

	 	 	  		 	
18.ESTIMATED

    TOTALPRICE

	 8. APP
CODE
 A
	  	  	 11. AS OF DATE

See Blk 16
	  	 13. DATE OF SUBSEQUENT
    SUBMISSION
 See Blk 16
	  	a. ADDRESSEE	  	b. COPIES	 	 	  		 
	  	  	  	  	  	 Draft
	  	Final	 	 	  		 
	  	  	  	  	  	  	 	 	  		 	
	  	  	  	  	  	 	  	Reg	  	Repro	 	 	  		 	
	
16. REMARKS
  

Blks 11-13: First report due within 15 days after the end of the first Fiscal Quarter post award. Subsequent reports due within 15 days of the end of each
FQ. Format provided to the contractor. Report should include expenditures to each item in the 3-Level WBS. Government review/approval is 15 days after receipt of first submittal. Provide changes to draft within 10 days of such request. Provide final
document within 10 days after approval of changes is received.
	  	DTRA/TMTI	  	 	  	1	  	 	 	 	  		 	
	  	DTRA/BCR	  	 	  	1	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	15. TOTAL    è	  	0	  	2	  	0	 	 	  		 	
	 G. PREPARED BY

 

	  	 H. DATE

 
 25 JUNE 09
	  	I. APPROVED BY	  	J. DATE	 	 	  		 	

					
	DD FORM 1423-2, AUG 96	  	PREVIOUS EDITION MAY BE USED.	  	                  Page        
of          Pages

  

 23. 

																											
	
CONTRACT DATA REQUIREMENTS LIST

(2 Data Items)
	  	 Form Approved

 OMB No. 0704-0188
	 	 	  		 	
	  

The public reporting burden for this collection of information is estimated to average 220 hours per response, including the time for reviewing
instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information,
including suggestions for reducing the burden, to the Department of Defense, Executive Services Directorate (0704-0188). Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for
failing to comply with a collection of information if it does not display a currently valid OMB control number. Please do not return your form to the above organization. Send completed form to the Government Issuing Contracting Officer for the
Contract/PR No. listed in Block E.
  
	 	 	  		 	
	 A.
CONTRACT LINE ITEM NO.
 NA
	  	 B. EXHIBIT

A
	  	 C. CATEGORY:

    TDP               TM    
           OTHER                    
	 	 	  		 	
	 D.
SYSTEM/ITEM
     Chemical/Biological Medical System
	  	E. CONTRACT/PR NO.	  	 F. CONTRACTOR

Trius Therapeutics
	 	 	  		 	
	 1. DATA ITEM NO.

A005
	  	 2. TITLE OF DATA ITEM

Annual Report
	  	 3. SUBTITLE

Cumulative Annual Progress Report
	 	 	  		 	17. PRICE GROUP
	 4. AUTHORITY (Data Acquisition
Document No.)
 DI-ADMN-80447
	  	 5. CONTRACT REFERENCE

NA
	  	 6. REQUIRING OFFICE

DTRA/TMTI
	 	 	  		 	 
	 7. DD 250 REQ

LT
	  	 9. DIST STATEMENT REQUIRED

 
 NA
	  	 10. FREQUENCY

See Blk 16
	  	 12.DATE OF FIRST SUBMISSION

See Blk 16
	  	
14.          DISTRIBUTION
	 	 	  		 	
18.ESTIMATED

    TOTALPRICE

	  	  	  	  	a. ADDRESSEE	  	b. COPIES	 	 	  		 	 
	  	  	  	  	  	Draft	  	Final	 	 	  		 	
	 8. APP CODE

A
	  	  	 11. AS OF DATE

See Blk 16
	  	 13.DATE OF SUBSEQUENT
SUBMISSION

 See Blk 16
	  	  	  	Reg	  	Repro	 	 	  		 	
	 16. REMARKS

 
 Blks 10-13: First submission within 15 days after the end of the first Fiscal Year
following award. Subsequent reports due within 15 days after the end of the Fiscal Year. Format as provided to contractor. Government review/approval is 15 days after receipt of first submittal. Provide changes to draft within 10 days of such
request. Provide final document within 10 days after approval of changes is received.
	  	DTRA/TMTI	  	 	  	1	  	 	 	 	  		 	
	  	DTRA/BCR	  	 	  	1	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	15. TOTAL    
è	  	0	  	2	  	0	 	 	  		 	
	 1. DATA ITEM NO.

A006
	  	 2. TITLE OF DATA ITEM

 Integrated Master Schedule
	  	 3. SUBTITLE

NA
	 	 	  		 	17. PRICE GROUP
	 4.
AUTHORITY (Data Acquisition Document No.)
 DI-MGMT-81650
	  	 5. CONTRACT REFERENCE

NA
	  	 6. REQUIRING OFFICE

DTRA/TMTI
	 	 	  		 	 
	 7. DD 250 REQ

LT
	  	
9. DIST STATEMENT
REQUIRED

 
 NA
	  	 10. FREQUENCY

See Blk 16
	  	 12. DATE OF FIRST SUBMISSION

See Blk 16
	  	 14.          DISTRIBUTION

	 	 	  		 	
18.ESTIMATED

    TOTALPRICE

	 8. APP
CODE
 A
	  	  	 11. AS OF DATE

See Blk 16
	  	 13. DATE OF SUBSEQUENT
SUBMISSION
 See Blk 16
	  	a. ADDRESSEE	  	b. COPIES	 	 	  		 	 
	  	  	  	  	  	Draft	  	Final	 	 	  		 	
	  	  	  	  	  	  	Reg	  	Repro	 	 	  		 	
	
16. REMARKS
  

Blk 10-13: First report due 15 days past award. Format provided to contractor. Subsequent reports due within 15 days of FQ end. Government review/approval
is 15 days after receipt of first submittal. Provide changes to draft within 10 days of such request. Provide final document within 10 days after approval of changes is received.
	  	DTRA/TMTI	  	 	  	1	  	 	 	 	  		 	
	  	DTRA/BCR	  	 	  	1	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	15. TOTAL    è	  	0	  	2	  	0	 	 	  		 	
	 G. PREPARED BY

 

	  	 H. DATE

 
 25 JUNE 09
	  	I. APPROVED BY	  	J. DATE	 	 	  		 	

					
	DD FORM 1423-2, AUG 96	  	PREVIOUS EDITION MAY BE USED.	  	                  Page        
of        Pages

  

 24. 

																											
	
CONTRACT DATA REQUIREMENTS LIST

(2 Data Items)
	  	 Form
Approved      
 OMB No. 0704-0188
	 	 	  		 	
	  

The public reporting burden for this collection of information is estimated to average 220 hours per response, including the time for reviewing
instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information,
including suggestions for reducing the burden, to the Department of Defense, Executive Services Directorate (0704-0188). Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for
failing to comply with a collection of information if it does not display a currently valid OMB control number. Please do not return your form to the above organization. Send completed form to the Government Issuing Contracting Officer for the
Contract/PR No. listed in Block E.
  
	 	 	  		 	
	 A.
CONTRACT LINE ITEM NO.
 NA
	  	 B. EXHIBIT

A
	  	 C. CATEGORY:

    TDP             TM      
       OTHER                    
	 	 	  		 	
	 D.
SYSTEM/ITEM
     Chemical/Biological Medical System
	  	E. CONTRACT/PR NO.	  	 F. CONTRACTOR

Trius Therapeutics
	 	 	  		 	
	 1. DATA ITEM NO.

A007
	  	 2. TITLE OF DATA ITEM

Final Report
	  	 3. SUBTITLE

Final Project Report
	 	 	  		 	17. PRICE GROUP
	 4. AUTHORITY (Data Acquisition
Document No.)
 DI-ADMN-084478
	  	 5. CONTRACT REFERENCE

NA
	  	 6. REQUIRING OFFICE

DTRA/TMTI
	 	 	  		 	 
	 7. DD 250 REQ

LT
	  	 9. DIST STATEMENT REQUIRED

 
 NA
	  	 10. FREQUENCY

1 Time
	  	 12.DATE OF FIRST SUBMISSION

See Blk 16
	  	
14.          DISTRIBUTION
	 	 	  		 	
18.ESTIMATED

    TOTALPRICE

	  	  	  	  	a. ADDRESSEE	  	b. COPIES	 	 	  		 	 
	  	  	  	  	  	Draft	  	Final	 	 	  		 	
	 8. APP CODE

A
	  	  	 11. AS OF DATE

Project end
	  	 13.DATE OF SUBSEQUENT
SUBMISSION

 NA
	  	  	  	Reg	  	Repro	 	 	  		 	
	 16. REMARKS

 
 Blk 12: Submission within 15 days of completion of final task. Contractor format
acceptable. Final report must include final summary of cost/financial data and project schedule in addition to performance. Government review/approval is 15 days after receipt of first submittal. Provide changes to draft within 10 days of such
request. Provide final document within 10 days after approval of changes is received.
	  	DTRA/TMTI	  	 	  	1	  	 	 	 	  		 	
	  	DTRA/BCR	  	 	  	1	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	15. TOTAL    
è	  	0	  	2	  	0	 	 	  		 	
	 1. DATA ITEM NO.

A008
	  	 2. TITLE OF DATA ITEM

 Miscellaneous Data Submissions
	  	 3. SUBTITLE

Point Paper, Briefings, TPP, PDP, Technical Presentations and Publications
	 	 	  		 	17. PRICE GROUP
	 4.
AUTHORITY (Data Acquisition Document No.)
 NA
	  	 5. CONTRACT REFERENCE

NA
	  	 6. REQUIRING OFFICE

DTRA/TMTI
	 	 	  		 	 
	 7. DD 250 REQ

LT
	  	
9. DIST STATEMENT
REQUIRED

 
 NA
	  	 10. FREQUENCY

As Required
	  	 12. DATE OF FIRST SUBMISSION

As Required
	  	 14.          DISTRIBUTION

	 	 	  		 	
18.ESTIMATED

    TOTALPRICE

	 8. APP
CODE
 A
	  	  	 11. AS OF DATE

As Required
	  	 13. DATE OF SUBSEQUENT
SUBMISSION
 As Required
	  	a. ADDRESSEE	  	b. COPIES	 	 	  		 	 
	  	  	  	  	  	Draft	  	Final	 	 	  		 	
	  	  	  	  	  	  	Reg	  	Repro	 	 	  		 	
	
16. REMARKS
  

Submission frequencies and dates will be coordinated. Deliverables shall be compatible electronic media. Unless format is provided, contractor format is
acceptable. Required submissions include Point Papers, Briefings, TPP, PDP, ACURO Approvals, HROB Approvals, Technical Presentations and Publications. Government review/approval is 15 days after receipt of first submittal. Provide changes to draft
within 10 days of such request. Provide final document within 10 days after approval of changes is received.
	  	DTRA/TMTI	  	 	  	1	  	 	 	 	  		 	
	  	DTRA/BCR	  	 	  	1	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	15. TOTAL    è	  	0	  	2	  	0	 	 	  		 	
	 G. PREPARED BY

 

	  	 H. DATE

 
 25 JUN 09
	  	I. APPROVED BY	  	J. DATE	 	 	  		 	

					
	DD FORM 1423-2, AUG 96	  	PREVIOUS EDITION MAY BE USED.	  	                  Page        
of        Pages

  

 25. 

																											
	
CONTRACT DATA REQUIREMENTS LIST

(2 Data Items)
	  	 Form Approved

 OMB No. 0704-0188
	 	 	  		 	
	  

The public reporting burden for this collection of information is estimated to average 220 hours per response, including the time for reviewing
instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information,
including suggestions for reducing the burden, to the Department of Defense, Executive Services Directorate (0704-0188). Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for
failing to comply with a collection of information if it does not display a currently valid OMB control number. Please do not return your form to the above organization. Send completed form to the Government Issuing Contracting Officer for the
Contract/PR No. listed in Block E.
  
	 	 	  		 	
	 A.
CONTRACT LINE ITEM NO.
 NA
	  	 B. EXHIBIT

A
	  	 C. CATEGORY:

    TDP               TM    
           OTHER                      
	 	 	  		 	
	 D.
SYSTEM/ITEM
     Chemical/Biological Medical System
	  	E. CONTRACT/PR NO.	  	 F. CONTRACTOR

Trius Therapeutics
	 	 	  		 	
	 1. DATA ITEM NO.

A009
	  	 2. TITLE OF DATA ITEM

Patents - Reporting of Subject Inventions
	  	 3. SUBTITLE

NA
	 	 	  		 	17. PRICE GROUP
	 4. AUTHORITY (Data Acquisition
Document No.)
 DI-MISC-80711A
	  	 5. CONTRACT REFERENCE

NA
	  	 6. REQUIRING OFFICE

DTRA/TMTI
	 	 	  		 	 
	 7. DD 250 REQ

LT
	  	 9. DIST STATEMENT REQUIRED

 
 NA
	  	 10. FREQUENCY

Annually
	  	 12.DATE OF FIRST SUBMISSION

See Blk 16
	  	
14.          DISTRIBUTION
	 	 	  		 	
18.ESTIMATED

    TOTALPRICE

	  	  	  	  	a. ADDRESSEE	  	b. COPIES	 	 	  		 	 
	  	  	  	  	  	Draft	  	Final	 	 	  		 	
	 8. APP CODE

A
	  	  	 11. AS OF DATE

See Blk 16
	  	 13.DATE OF SUBSEQUENT
SUBMISSION

 See Blk 16
	  	  	  	Reg	  	Repro	 	 	  		 	
	 16. REMARKS

 
 Blk 11-13: Provide report(s) every 12 months from the date of the contract as
identified in the DFARS 252.227-7039 (Patents-Reporting Subject Inventions (DD Form 882 attached) and FAR 52.227-11.
	  	DTRA/TMTI	  	 	  	1	  	 	 	 	  		 	
	  	DTRA/BCR	  	 	  	1	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	15. TOTAL    
è	  	0	  	2	  	0	 	 	  		 	
	 1. DATA ITEM NO.

A010
	  	 2. TITLE OF DATA ITEM

 Regulatory Approval and Technical Data Packages
	  	 3. SUBTITLE

Submission Report (Regulatory Appr. Docs)
	 	 	  		 	17. PRICE GROUP
	 4.
AUTHORITY (Data Acquisition Document No.)
 NA
	  	 5. CONTRACT REFERENCE

NA
	  	 6. REQUIRING OFFICE

DTRA/TMTI
	 	 	  		 	 
	 7. DD 250 REQ

LT
	  	
9. DIST STATEMENT
REQUIRED

 
 NA
	  	 10. FREQUENCY

See Blk 16
	  	 12. DATE OF FIRST SUBMISSION

See Blk 16
	  	 14.          DISTRIBUTION

	 	 	  		 	
18.ESTIMATED

    TOTALPRICE

	 8. APP
CODE
 A
	  	  	 11. AS OF DATE

See Blk 16
	  	 13. DATE OF SUBSEQUENT
SUBMISSION
 See Blk 16
	  	a. ADDRESSEE	  	b. COPIES	 	 	  		 	 
	  	  	  	  	  	Draft	  	Final	 	 	  		 	
	  	  	  	  	  	  	Reg	  	Repro	 	 	  		 	
	
16. REMARKS
  

Blk 10-13: Contractor will provide the Government copies of all technical data generated by the contractor prior to and during performance of contract
necessary to pursue FDA approval of IND, NDA, and notify the Government of FDA decisions. All written communications to and/or from the FDA will be provided to the Government. Government review/approval is 15 days after receipt of first submittal.
Provide changes to draft within 10 days of such request. Provide final document within 10 days after approval of changes is received.
	  	DTRA/TMTI	  	 	  	1	  	 	 	 	  		 	
	  	DTRA/BCR	  	 	  	1	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	15. TOTAL    è	  	0	  	2	  	0	 	 	  		 	
	 G. PREPARED BY

 

	  	 H. DATE

 
 25 JUN 09
	  	I. APPROVED BY	  	J. DATE	 	 	  		 	

					
	DD FORM 1423-2, AUG 96	  	PREVIOUS EDITION MAY BE USED.	  	              Page        
of        Pages

  

 26. 

																											
	
CONTRACT DATA REQUIREMENTS LIST

(2 Data Items)
	  	 Form
Approved      
 OMB No. 0704-0188
	 	 	  		 	
	  

The public reporting burden for this collection of information is estimated to average 220 hours per response, including the time for reviewing
instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information,
including suggestions for reducing the burden, to the Department of Defense, Executive Services Directorate (0704-0188), Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for
failing to comply with a collection of information if it does not display a currently valid OMB control number. Please do not return your form to the above organization. Send completed form to the Government Issuing Contracting Officer for the
Contract/PR No. listed in Block E.
  
	 	 	  		 	
	 A.
CONTRACT LINE ITEM NO.
 NA
	  	 B. EXHIBIT

A
	  	 C. CATEGORY:

    TDP             TM      
       OTHER                    
	 	 	  		 	
	 D.
SYSTEM/ITEM
     Chemical/Biological Medical System
	  	E. CONTRACT/PR NO.	  	 F. CONTRACTOR

Trius Therapeutics
	 	 	  		 	
	 1. DATA ITEM NO.

A011
	  	 2. TITLE OF DATA ITEM

In Process Review
	  	 3. SUBTITLE

NA
	 	 	  		 	17. PRICE GROUP
	 4. AUTHORITY (Data Acquisition
Document No.)
 DI-MGMT-80227 & DI-MGMT-80555A
	  	 5. CONTRACT REFERENCE

NA
	  	 6. REQUIRING OFFICE

DTRA/TMTI
	 	 	  		 	 
	 7. DD 250 REQ

LT
	  	 9. DIST STATEMENT REQUIRED

 
 NA
	  	 10. FREQUENCY

every 6 months
	  	 12.DATE OF FIRST SUBMISSION

See Blk 16
	  	
14.          DISTRIBUTION
	 	 	  		 	
18.ESTIMATED

    TOTALPRICE

	  	  	  	  	a. ADDRESSEE	  	b. COPIES	 	 	  		 	 
	  	  	  	  	  	Draft	  	Final	 	 	  		 	
	 8. APP CODE

A
	  	  	 11. AS OF DATE

See Blk 16
	  	 13.DATE OF SUBSEQUENT
SUBMISSION

 See Blk 16
	  	  	  	Reg	  	Repro	 	 	  		 	
	 16. REMARKS

 
 Blk 11 – 13: Contractor present project status formally to the Government every
6 months in accordance with a Government provided agenda. Government review/approval is 15 days after receipt of first submittal. Provide changes to draft within 10 days of such request. Provide final document within 10 days after approval of
changes is received.
	  	DTRA/TMTI	  	 	  	1	  	 	 	 	  		 	
	  	DTRA/BCR	  	 	  	1	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	15. TOTAL    
è	  	0	  	2	  	0	 	 	  		 	
	 1. DATA ITEM NO.

A012
	  	 2. TITLE OF DATA ITEM

 Expenditure Forecast
	  	 3. SUBTITLE

Project Spend Plan
	 	 	  		 	17. PRICE GROUP
	 4.
AUTHORITY (Data Acquisition Document No.)
 DI-MGMT-81468
	  	 5. CONTRACT REFERENCE

NA
	  	 6. REQUIRING OFFICE

DTRA/TMTI
	 	 	  		 	 
	 7. DD 250 REQ

LT
	  	
9. DIST STATEMENT
REQUIRED

 
 NA
	  	 10. FREQUENCY

See Blk 16
	  	 12. DATE OF FIRST SUBMISSION

See Blk 16
	  	 14.          DISTRIBUTION

	 	 	  		 	
18.ESTIMATED

    TOTALPRICE

	 8. APP
CODE
 A
	  	  	 11. AS OF DATE

See Blk 16
	  	 13. DATE OF SUBSEQUENT
SUBMISSION
 See Blk 16
	  	a. ADDRESSEE	  	b. COPIES	 	 	  		 	 
	  	  	  	  	  	Draft	  	Final	 	 	  		 	
	  	  	  	  	  	  	Reg	  	Repro	 	 	  		 	
	
16. REMARKS
  

Blks 10-13: Contractor will provide an updated expenditure forecast reflecting actual negotiated costs over the lifetime of the project 15 days past
award, and will update the forecast as requested by the Government. Format as provided to contractor. Government review/approval is 15 days after receipt of first submittal. Provide changes to draft within 10 days of such request. Provide final
document within 10 days after approval of changes is received.
	  	DTRA/TMTI	  	 	  	1	  	 	 	 	  		 	
	  	DTRA/BCR	  	 	  	1	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	15. TOTAL    è	  	0	  	2	  	0	 	 	  		 	
	 G. PREPARED BY

 

	  	 H. DATE

 
 25 JUN 09
	  	I. APPROVED BY	  	J. DATE	 	 	  		 	

					
	DD FORM 1423-2, AUG 96	  	PREVIOUS EDITION MAY BE USED.	  	                  Page        
of        Pages

  

 27. 

																											
	
CONTRACT DATA REQUIREMENTS LIST

(1 Data Items)
	  	 From Approved

 OMB No. 0704-0188
	 	 	  		 	
	  

The public reporting burden for this collection of information is estimated to average 110 hours per response, including the time for reviewing
instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information,
including suggestions for reducing the burden, to the Department of Defense, Executive Services Directorate (0704-0188), Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for
failing to comply with a collection of information if it does not display a currently valid OMB control number. Please do not return your form to the above organization. Send completed form to the Government Issuing Contracting Officer for the
Contract/PR No. listed in Block E.
  
	 	 	  		 	
	 A.
CONTRACT LINE ITEM NO.
 NA
	  	 B. EXHIBIT

A
	  	 C. CATEGORY:

    TDP                  TM
               OTHER  
                    
	 	 	  		 	
	 D.
SYSTEM/ITEM
     Chemical/Biological Medical System
	  	 E. CONTRACT/PR NO.

NA
	  	 F. CONTRACTOR

Trius Therapeutics
	 	 	  		 	
	 1. DATA ITEM NO.

A013
	  	 2. TITLE OF DATA ITEM

Project Management Plan
	  	 3. SUBTITLE

NA
	 	 	  		 	17. PRICE GROUP
	 4. AUTHORITY (Data Acquisition
Document No.)
 DI-MGMT-80004A
	  	 5. CONTRACT REFERENCE

NA
	  	 6. REQUIRING OFFICE

DTRA/TMTI
	 	 	  		 	 
	 7. DD 250 REQ

LT
	  	 9. DIST STATEMENT REQUIRED

 
 NA
	  	 10. FREQUENCY

See Blk 16
	  	 12.DATE OF FIRST SUBMISSION

See Blk 16
	  	
14.          DISTRIBUTION
	 	 	  		 	
18.ESTIMATED

    TOTALPRICE

	  	  	  	  	a. ADDRESSEE	  	b. COPIES	 	 	  		 	 
	  	  	  	  	  	Draft	  	Final	 	 	  		 	
	 8. APP CODE

A
	  	  	 11. AS OF DATE

See Blk 16
	  	 13.DATE OF SUBSEQUENT
SUBMISSION

 See Blk 16
	  	  	  	Reg	  	Repro	 	 	  		 	
	 16. REMARKS

 
 Includes organizational chart, initial WBS, initial Integrated Master Plan, Risk
Management Plan, Regulatory Affairs Plan. Formats provided to contractor. Due within 15 days past award.
	  	DTRA/TMTI	  	 	  	1	  	 	 	 	  		 	
	  	DTRA/BCR	  	 	  	1	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	 	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	 	  	 	  	 	  	 	 	 	  		 	
	  	15. TOTAL    
è	  	0	  	2	  	0	 	 	  		 	
	 G. PREPARED BY

 

	  	 H. DATE

 
 25 JUN 09
	  	I. APPROVED BY	  	J. DATE	 	 	  		 	

					
	DD FORM 1423-1, FEB 2001	  	PREVIOUS EDITION MAY BE USED.	  	                  Page        
of        Pages

  

 28. 

 EXHIBIT B 

DTRA Requirements 
  

			
	 #
	  	CLAUSES INCORPORATED BY REFERENCE
		
	 1
	  	52.202-1 Definitions JUL 2004
		
	 2
	  	52.203-3 Gratuities APR 1984
		
	 3
	  	52.203-5 Covenant Against Contingent Fees APR 1984
		
	 4
	  	52.203-6 Restrictions On Subcontractor Sales To The Government SEP 2006
		
	 5
	  	52.203-7 Anti-Kickback Procedures JUL 1995
		
	 6
	  	52.203-8 Cancellation, Rescission, and Recovery of Funds for Illegal or Improper Activity
		
	 7
	  	52.203-10 Price Or Fee Adjustment For Illegal Or Improper Activity JAN 1997
		
	 8
	  	52.203-12 Limitation On Payments To Influence Certain Federal Transactions
		
	 9
	  	52.203-13 Contractor Code of Business Ethics and Conduct DEC 2008
		
	 10
	  	52.203-14 Display of Hotline Poster(s) DEC 2007
		
	 11
	  	52.204-4 Printed or Copied Double-Sided on Recycled Paper AUG 2000
		
	 12
	  	 52.204-7 Central Contractor Registration APR 2008

52.209-6 Protecting the Government’s Interest When Subcontracting With Contractors

		
	 13
	  	Debarred, Suspended, or Proposed for Debarment
		
	 14
	  	52.215-2 Audit and Records–Negotiation MAR 2009, Alternate II
		
	 15
	  	52.215-8 Order of Precedence–Uniform Contract Format OCT 1997
		
	 16
	  	52.215-10 Price Reduction for Defective Cost or Pricing Data OCT 1997
		
	 17
	  	52.215-12 Subcontractor Cost or Pricing Data OCT 1997
		
	 18
	  	52.215-15 Pension Adjustments and Asset Reversions OCT 2004
		
	 19
	  	 52.215-17 Waiver of Facilities Capital Cost of Money OCT 1997

52.215-18 Reversion or Adjustment of Plans for Postretirement Benefits (PRB) Other than

		
	 20
	  	Pensions
		
	 21
	  	 52.215-19 Notification of Ownership Changes OCT 1997

52.215-21 Requirements for Cost or Pricing Data or Information Other Than Cost or Pricing Data-

		
	 22
	  	-Modifications
		
	 23
	  	52.215-23 Limitations on Pass-Through Charges OCT 2009
		
	 24
	  	52.216-7 Allowable Cost And Payment DEC 2002
		
	 25
	  	52.216-8 Fixed Fee MAR 1997
		
	 26
	  	52.219-8 Utilization of Small Business Concerns MAY 2004
		
	 27
	  	52.222-3 Convict Labor JUN 2003
		
	 28
	  	52.222-21 Prohibition Of Segregated Facilities FEB 1999
		
	 29
	  	 52.222-26 Equal Opportunity MAR 2007

52.222-35 Equal Opportunity For Special Disabled Veterans, Veterans of the Vietnam Era, and

		
	 30
	  	Other Eligible Veterans
		
	 31
	  	 52.222-36 Affirmative Action For Workers With Disabilities JUN 1998

52.222-37 Employment Reports On Special Disabled Veterans, Veterans Of The Vietnam Era, and

		
	 32
	  	Other Eligible Veterans
		
	 33
	  	52.222-50 Combating Trafficking in Persons FEB 2009
		
	 34
	  	52.222-54 Employment Eligibility Verification JAN 2009
		
	 35
	  	52.223-6 Drug-Free Workplace MAY 2001

  

 29. 

			
	 36
	  	2.223-14 Toxic Chemical Release Reporting AUG 2003
		
	 37
	  	52.225-13 Restrictions on Certain Foreign Purchases JUN 2008
		
	 38
	  	52.227-1 Authorization and Consent DEC 2007
		
	 39
	  	52.227-1 Alt I Authorization And Consent (Dec 2007) - Alternate I APR 1984
		
	 40
	  	52.227-2 Notice And Assistance Regarding Patent And Copyright Infringement
		
	 41
	  	52.227-11 Patent Rights–Ownership By The Contractor DEC 2007 JDTRA1-10-C-0004
		
	 42
	  	52.227-11 Alt II Patent Rights–Ownership by the Contractor (Dec 2007) -Alternate II
		
	 43
	  	52.228-7 Insurance–Liability To Third Persons MAR 1996
		
	 44
	  	52.229-10 State of New Mexico Gross Receipts and Compensating Tax APR 2003
		
	 45
	  	52.232-9 Limitation On Withholding Of Payments APR 1984
		
	 46
	  	52.232-17 Interest OCT 2008
		
	 47
	  	52.232-23 Assignment Of Claims JAN 1986
		
	 48
	  	52.232-23 Alt I Assignment of Claims (Jan 1986) - Alternate I APR 1984
		
	 49
	  	52.232-25 Prompt Payment OCT 2008
		
	 50
	  	52.232-25 Alt I Prompt Payment (Oct 2008) Alternate I FEB 2002
		
	 51
	  	52.232-33 Payment by Electronic Funds Transfer–Central Contractor Registration
		
	 52
	  	52.233-1 Disputes JUL 2002
		
	 53
	  	52.233-1 Alt I Disputes (Jul 2002) - Alternate I DEC 1991
		
	 54
	  	52.233-3 Protest After Award AUG 1996
		
	 55
	  	52.233-3 Alt I Protest After Award (Aug 1996) - Alternate I JUN 1985
		
	 56
	  	52.233-4 Applicable Law for Breach of Contract Claim OCT 2004
		
	 57
	  	52.242-1 Notice of Intent to Disallow Costs APR 1984
		
	 58
	  	52.242-3 Penalties for Unallowable Costs MAY 2001
		
	 59
	  	52.242-4 Certification of Final Indirect Costs JAN 1997
		
	 60
	  	52.242-13 Bankruptcy JUL 1995
		
	 61
	  	52.243-2 Changes–Cost-Reimbursement AUG 1987
		
	 62
	  	52.243-2 Alt V Changes–Cost-Reimbursement (Aug 1987) - Alternate V APR 1984
		
	 63
	  	52.244-2 Subcontracts JUN 2007
		
	 64
	  	52.244-5 Competition In Subcontracting DEC 1996
		
	 65
	  	52.244-6 Subcontracts for Commercial Items AUG 2009
		
	 66
	  	52.245-1 Government Property JUN 2007
		
	 67
	  	52.245-1 (Dev) Government Property (June 2007) JUN 2007
		
	 68
	  	52.245-9 Use And Charges JUN 2007
		
	 69
	  	 52.246-25 Limitation Of Liability–Services FEB 1997

52.249-5 Termination for Convenience of the Government (Educational and Other Nonprofit Institutions). (Sept. 1996)

		
	 70
	  	
		
	 71
	  	52.249-14 Excusable Delays APR 1984
		
	 72
	  	52.251-1 Government Supply Sources APR 1984
		
	 73
	  	52.253-1 Computer Generated Forms JAN 1991
		
	 74
	  	252.201-7000 Contracting Officer’s Representative DEC 1991
		
	 75
	  	252.203-7000 Requirements Relating to Compensation of Former DoD Officials 252.203-7001 Prohibition On Persons Convicted of Fraud or Other
Defense-Contract-Related
		
	 76
	  	Felonies
		
	 77
	  	252.203-7002 Requirement to Inform Employees of Whistleblower Rights JAN 2009
		
	 78
	  	

  

 30. 

			
	 79
	  	52.204-7003 Control Of Government Personnel Work Product APR 1992
		
	 80
	  	252.204-7004 Alt A Central Contractor Registration (52.204-7) Alternate A SEP 2007
		
	 81
	  	252.204-7009 Requirements Regarding Potential Access to Export-Controlled Items
		
	 82
	  	 252.205-7000 Provision Of Information To Cooperative Agreement Holders DEC 1991

252.209-7004 Subcontracting With Firms That Are Owned or Controlled By The Government of a

		
	 83
	  	Terrorist Country
		
	 84
	  	 252.211-7003 Item Identification and Valuation AUG 2008

252.211-7007 Reporting of Government-Furnished Equipment in the DoD Item Unique

		
	 85
	  	Identification (IUID) Registry
		
	 86
	  	252.215-7000 Pricing Adjustments DEC 1991
		
	 87
	  	 252.215-7002 Cost Estimating System Requirements DEC 2006

252.222-7999 (Dev) Additional Requirements and Responsibilities Restricting the Use of

		
	 88
	  	Mandatory Arbitration Agreements (Deviation) 252.225-7004 Report of Intended Performance Outside the United States and Canada–
		
	 89
	  	Submission after Award
		
	 90
	  	252.225-7006 Quarterly Reporting of Actual Contract Performance Outside the United States
		
	 91
	  	 252.225-7012 Preference For Certain Domestic Commodities DEC 2008

252.226-7001 Utilization of Indian Organizations and Indian-Owned Economic Enterprises, and

		
	 92
	  	Native Hawaiian Small Business Concerns
		
	 93
	  	Economic Enterprises, and Native Hawaiian Small Business
		
	 94
	  	252.227-7013 Rights in Technical Data–Noncommercial Items NOV 1995
		
	 95
	  	 252.227-7016 Rights in Bid or Proposal Information JUN 1995

252.227-7025 Limitations on the Use or Disclosure of Government-Furnished Information

		
	 96
	  	Marked with Restrictive Legends
		
	 97
	  	252.227-7027 Deferred Ordering Of Technical Data Or Computer Software APR 1988
		
	 98
	  	252.227-7030 Technical Data–Withholding Of Payment MAR 2000
		
	 99
	  	252.227-7037 Validation of Restrictive Markings on Technical Data SEP 1999
		
	 100
	  	252.227-7039 Patents–Reporting Of Subject Inventions APR 1990
		
	 101
	  	252.231-7000 Supplemental Cost Principles DEC 1991
		
	 102
	  	252.232-7003 Electronic Submission of Payment Requests and Receiving Reports
		
	 103
	  	252.232-7010 Levies on Contract Payments DEC 2006
		
	 104
	  	252.235-7002 Animal Welfare DEC 1991
		
	 105
	  	252.235-7010 Acknowledgment of Support and Disclaimer MAY 1995 (shown below)
		
	 106
	  	252.235-7011 Final Scientific or Technical Report NOV 2004
		
	 107
	  	252.243-7002 Requests for Equitable Adjustment MAR 1998
		
	 108
	  	252.244-7000 Subcontracts for Commercial Items and Commercial Components (DoD Contracts)
		
	 109
	  	252.247-7023 Transportation of Supplies by Sea MAY 2002
		
	 110
	  	252.247-7024 Notification Of Transportation Of Supplies By Sea MAR 2000
		
	 111
	  	252.251-7000 Ordering From Government Supply Sources NOV 2004
		
		  	252.235-7010 Acknowledgment of Support and Disclaimer.

 As
prescribed in 235.071(c), use the following clause: 
 ACKNOWLEDGMENT OF SUPPORT AND DISCLAIMER (MAY 1995) 

(a) The Contractor shall include an acknowledgment of the Government’s support in the publication of any material based on or developed under this
contract, stated in the following terms: This material is based upon work supported by the (name of contracting agency(ies)) under Contract No. (Contracting agency(ies) contract number(s)). 

 

 31. 

 (b) All material, except scientific articles or papers published in scientific journals, must, in addition
to any notices or disclaimers by the Contractor, also contain the following disclaimer: Any opinions, findings and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the
(name of contracting agency(ies)). 
 Applicable Clauses Incorporated by Full Text 

252.235-9001 PROHIBITION OF USE OF LABORATORY ANIMALS (OCT 2008)(DTRA) No animal studies may be conducted using DOD funds until Animal Care and Use
Review Office (ACURO) approval has been granted. Studies involving non human primates, dogs, cats, or marine mammals will require site visit by a DoD laboratory animal veterinarian. The recipient (including subcontractors) is expressly forbidden to
use laboratory animals in any manner whatsoever without the express written approval of the US Army Medical Research and Material Command (MRMC), Animal Care and Use Review Office (ACURO). You must complete the ACURO Animal Use Appendix for Research
Involving Animals found at the following web site: https://mrmcwww.army.mil/AnimalAppendix.asp. Please submit the completed ACURO appendix, contact information, the DTRA contract number and a copy of the contract for processing to the email address
listed at the ACURO website for processing. You will receive written approval to begin research under the applicable protocol proposed for this award from the US Army MRMC ACURO under separate email to the recipient and Principal Investigator. A
copy of this approval will be provided to the Defense Threat Reduction Agency (DTRA) for the official file. Noncompliance with any provision of this clause may result in the termination of the award. 

252.209-9002 NON-GOVERNMENT SUPPORT PERSONNEL (JAN 2008) 

The following companies may have access to contractor information, technical data or computer software that may be marked as proprietary
or otherwise marked with restrictive legends: Suntiva LLC (Formerly C-Systems International Corporation )(contract specialist support); Systems Research and Analysis (SRA, managing JPRAS) and The Tauri Group (Advisory and Assistance Services). Each
contract contains organizational conflict of interest provisions and/or includes contractual requirements for non-disclosure of proprietary contractor information or data/software marked with restrictive legends. The contractor, by submitting a
proposal or entering into this contract, is deemed to have consented to the disclosure of its information to Suntiva LLC, SRA and The Tauri Group under the conditions and limitations described herein. 

252.245-9000 Government Property (AUG 2009) 

(a) In accordance with FAR 52.245-1(b), Property Management, and FAR 52.245-1(f), Contractor Plans and Systems, the Contractor shall have a system to
manage (control, use, preserve, protect, repair and maintain) Government property in its possession. 
 (b) The Contract Data Requirements Lists
(CDRLs) associated with the Property for this Contract are contained in Exhibit “A” and included in Section J of this contract. The spreadsheet required by the CDRL entitled “Master Government Property List (MGPL) will be incorporated
in Section J of this contract. 
 (c) The Contractor shall provide to the Government an updated MGPL according to the CDRL. 

(d) The Government Site Visits/Physical Inventory – The DTRA will annually verify the Property in the Possession of the Contractor. The
Contactor’s Point of Contact shall coordinate with the Program Manager/Contracting Officer Representative or DTRA Accountable Property Officer (APO) on prearranged site visits upon request. 

(e) The Contractor shall annually conduct and provide to the DTRA a physical inventory report of ALL Government Property in its possession according to
the Master Government Property List (Physical Inventory) CDRL. 
 (f) The physical inventory report shall be validated/confirmed via signature
by both the Contractor’s Property Administrator and the DTRA’s Government Representative (i.e. COR, APO, etc.). 
  

 32. 

 Inventory discrepancies must be reported immediately to the Contracting Officer, COR/Program Manager and
resolved by the DTRA APO. 
 (g) The Contractor shall provide all CDRL reports to the Government electronically in a spreadsheet using Microsoft
Office Excel. Unless otherwise specified, the contractor shall submit all data through the IUID Registry. 
 252.216-9003 CONSULTANTS (OCT 1998)

 Services of consultants shall be at rates and for periods approved in advance by the Contracting Officer. Requests for approval shall be
submitted to the Contracting Officer sufficiently in advance of the need to use a consultant under this Contract. The request shall include (a) a copy of the proposed consultant agreement, (b) a brief biography of the consultant, and
(c) an indication of the area(s) in which consultant’s expertise will be utilized and why it is essential for contract performance. In addition, significant deviations from the dollar amount approved for consultant services, or changes in
the consultants to be utilized, must likewise be approved in advance upon submission of adequate justification. 
 52.222-2 PAYMENT FOR OVERTIME
PREMIUMS (JUL 1990) 
 (a) The use of overtime is authorized under this contract if the overtime premium cost does not exceed 0.00 or the
overtime premium is paid for work – (1) Necessary to cope with emergencies such as those resulting from accidents, natural disasters, breakdowns of production equipment, or occasional production bottlenecks of a sporadic nature;
(2) By indirect-labor employees such as those performing duties in connection with administration, protection, transportation, maintenance, standby plant protection, operation of utilities, or accounting; (3) To perform tests, industrial
processes, laboratory procedures, loading or unloading of transportation conveyances, and operations in flight or afloat that are continuous in nature and cannot reasonably be interrupted or completed otherwise; or (4) That will result in lower
overall costs to the Government. 
 (b) Any request for estimated overtime premiums that exceeds the amount specified above shall include all
estimated overtime for contract completion and shall – 
 (1) Identify the work unit; e.g., department or section in which the requested
overtime will be used, together with present workload, staffing, and other data of the affected unit sufficient to permit the Contracting Officer to evaluate the necessity for the overtime; 

(2) Demonstrate the effect that denial of the request will have on the contract delivery or performance schedule; (3) Identify the extent to
which approval of overtime would affect the performance or payments in connection with other Government contracts, together with identification of each affected contract; and (4) Provide reasons why the required work cannot be performed by
using multishift operations or by employing additional personnel exceptions in paragraph (a)(1) through (a)(4) of the clause. 
 RIGHTS IN
MATERIAL 
 RIGHTS IN MATERIAL – [...***...] 

(a) Definitions. As used in this clause: 

(1) “Collection” means [...***...] this contract. 

(2) “Collected exclusively with government funds” means [...***...] expense. 

(3) “Material” refers to [...***...] above. 

(4) “Unlimited rights” means rights to [...***...] in whole or in part, in any manner, and for any purpose whatsoever, and to have or
authorize others to do so. 
 (b) Rights in [...***...] rights: 

(1) Unlimited rights. The Government shall [...***...] rights in [...***...] that are – 

(i) [...***...] which have been or will be [...***...]; 

 

 ***Confidential Treatment Requested 

33. 

 (ii) [...***...] for this contract, when the [...***...]. 

(c) Specifics. The Contractor and the Government agree to the following: 

(1) The [...***...] shall reside with the subcontractor – [...***...]. 

(2) The unlimited rights conveyed to the U.S. Government, under this contract, does not [...***...]. 

(3) Copies of the collection, as defined under section (a) of this clause, will be made available to U.S. Government agencies, to include Department
of Defense, upon request. 
 (4) The [...***...] prior to execution of this contract [...***...]. 

(5) Upon completion of the contract, the collection – as defined under section (a) of this clause – [...***...] the U.S. Government.

 H.1 PATENT RIGHTS 
 RETENTION BY
THE CONTRACTOR 
 In accordance with FAR 52.227-11(f), reporting on utilization of subject inventions: 

The Contractor agrees to submit, periodic reports annually on the utilization of a subject invention or efforts at obtaining such utilization that are
being made by the Contractor or its licensees or assignees. 
  

 ***Confidential Treatment Requested 

34. 

 EXHIBIT C 

Budget 
 (See
Attached) 
  

 35. 

 UCSD PROPOSAL SIGNATURE PAGE 

The Regents of the University of California 

University of California, San Digo 

UCSD#            20092529R2       
      
  

					
	 	 	Principal Investigator:	  	Co-Principal
Investigator:
	Last Name	 	Fenical	  	 
	First Name	 	William	  	 
	Title	 	Distinguished Professor	  	 
	Department/ORU	 	CMBB	  	 
	Mail Code	 	Mail Code 0204	  	 
	Phone #	 	858-534-2133	  	 
	Fax #	 	858-534-1318	  	 
	Email	 	wfenical@ucsd.edu	  	 
	 	 	Agency Information:
	Agency Name	 	DTRA via Trius Therapeutics	  	if applicable, include the following information:
	Contact Name	 	Mark Stidham	  	Award #
	Contact Phone	 	858-452-0370 X229	  	PA/RFA/RFP. etc #        
HDTRA1-09-CHEM-BIO-BAA
	Street Address	 	6310 Nancy Ridge Drive, Suite 105	  	Other required agency information, such as DUNS Number, etc.
	City, State, Zip	 	San
Diego                            CA        92121	  	 
	Proposal Title	 	Broad Spectrum Antibacterial Therapeutics from Marine Natural Products

	 	 
	 Project Begin Date

 
	 	            
04/12/10            Project End
Date            04/11/15            Total Costs
Requested            $4,306,007

  

			
	Principal Investigator	    	
		
	
 

 Principal Investigator Signature
	    	 4/1/10

Date

		
	Co-Principal Investigator	    	
		
	  

Co-Principal Investigator Signature
	    	  

Date

	
	OCGA Official Authorized to Sign on Behalf of The Regents
		
	
 

 Signature
	    	 4/1/10

Date

  

	
	 Nancy A. F. Wilson, Manager, Office of Contract and Grant
Administration
 Print or Type Name and Title

 

							
	
Please send award documents as indicated below:

 

	 ̈ For General Campus and Health Sciences
Proposals	  	x For Scripps Institution of Oceanography
Proposals
	 	 		 
	Mailing Address:	 	Courier Address:	  	Mailing Address:	  	Courier Address:
	 University of California-San
Diego
 Office of Contract and Grant Administration

9500 Gilman Drive, Dept 0934

La Jolla, California 92093-0934

Phone # 858-534-3330

Fax # 858-534-0280
  
	 	 University of California-San Diego

 Office of Contract and Grant Administration

10300 N Torrey Pines Road, 2nd Floor

La Jolla, California 92037

Phone # 858-534-3330

Fax # 858-534-0280
	  	 University of California-San Diego

SIO Contract and Grant Office

9500 Gilman Drive, Dept 0210

La Jolla, California 92093-0210

Phone # 858-534-4570

Fax # 858-534-9642
	  	 University of
California-San Diego
 SIO Contract and Grant Office

8622 Discovery Way, Room 116

La Jolla, California 92037

Phone # 858-534-4570

Fax # 858-534-9642

Office of Contract and Grant Administration 9/2006 

 [...***...] 

 

 ***Confidential Treatment Requested 

 [...***...]  

 

 ***Confidential Treatment Requested 

 [...***...] 

 

 ***Confidential Treatment Requested 

 [...***...]  

 

 ***Confidential Treatment Requested 

 [...***...]  

 

 ***Confidential Treatment Requested 

 [...***...]  

 

 ***Confidential Treatment Requested 

 [...***...]  

 

 ***Confidential Treatment Requested 

 [...***...] 

 

 ***Confidential Treatment Requested 

 [...***...] 

[...***...] 
  

 ***Confidential Treatment Requested 

 [...***...] 

[...***...] 
  

 ***Confidential Treatment Requested 

 [...***...] 

[...***...] 
  

 ***Confidential Treatment Requested 

 [...***...] 

[...***...] 
  

 ***Confidential Treatment RequestedConsent and Amendment Agreement between Silicon Valley Bank and Motricity, Inc.

 Exhibit 10.28 

Consent and Amendment Agreement 
  

	Borrower:	Motricity, Inc. 

  

	Address:	 601
108th Avenue NE, Suite 900 

Bellevue, Washington 98004 

THIS CONSENT AND AMENDMENT AGREEMENT (this “Consent”) is dated as of June 7, 2010 and is by and between SILICON VALLEY BANK
(“Bank”) and MOTRICITY, INC. a Delaware corporation (“Borrower”). 
 RECITALS 

A. Bank and Borrower have entered into that certain Loan and Security Agreement dated as of June 27, 2007, as amended by that certain
Amendment to Loan and Security Agreement dated as of April 13, 2009, as amended by that certain Amendment to Loan and Security Agreement dated as of September 25, 2009 and as amended by that certain Loan and Security Agreement dated as of
December 23, 2009 (as so amended, the “Loan Agreement”). 
 B. Bank has extended credit to Borrower for the purposes
permitted in the Loan Agreement. 
 C. Borrower is entering into an amendment of its certificate of incorporation to modify certain
terms relating to, among other things, its Series H Preferred Stock (the “Certificate Modifications”). 
 D. Borrower has
requested that Bank consent to the following (collectively, the “Transactions”): 
 1. On or about September 29, 2009,
Borrower effected a buyback of approximately 2,500,000 shares of Borrower’s Common Stock for an aggregate purchase price of approximately $1,250,000; 

2. In December 2009, Borrower repurchased approximately 332,000 shares of Common Stock of Borrower from its chief executive officer as
consideration for the payment of a loan outstanding from such person to the Borrower; 
 3. (A) Borrower is planning to implement a 15 to
1 reverse stock split of Borrower’s Common Stock that will result in the creation of fractional shares of the newly-constituted Common Stock of Borrower; (B) Borrower expects that some or all of its preferred stock will convert to Common
Stock upon its initial public offering that also will result in the creation of fractional shares of its Common Stock; and (C) in connection with the foregoing, Borrower desires the ability to pay cash to all such holders of such fractional
shares of Common Stock in an aggregate amount of approximately $500,000; 

 4. On or about the date hereof, Borrower is entering into an agreement to use an Affiliate entity,
Advanced Equities, Inc. (“AEI”), as a financial advisor in connection with the Borrower’s proposed initial public offering of its common stock, and to pay AEI fees in the aggregate amount of $2,000,000 in connection therewith; and

 5. The Certificate Modifications provide for, among other things and subject to the conditions set forth therein, the payment of
dividends to holders of Series H Preferred Stock of the Borrower through the issuance of additional shares of Series H Preferred Stock of Borrower to such holders. 

AGREEMENT 

NOW, THEREFORE, in consideration of the foregoing recitals and other good and valuable consideration, the
receipt and adequacy of which is hereby acknowledged, and intending to be legally bound, the parties hereto agree as follows: 
 1. Definitions.
Capitalized terms used but not defined in this Amendment shall have the meanings given to them in the Loan Agreement. 
 2. Consent. The
Transactions require the approval of Bank under the Loan Agreement, including, without limitation, pursuant to Sections 7.7 and 7.8, among other sections thereof, and Borrower has requested that Bank consent to the Transactions. Bank is agreeable
thereto and therefore Bank does hereby consent to the Transactions. 
 3. Acknowledgment. Bank hereby acknowledges the Certificate Modifications,
including the pay-in-kind dividends referred to in Recital D.5, provided that such acknowledgment does not modify or amend any term or provision of the Loan Agreement, including, without limitation, covenants pertaining to redemptions, cash
dividends and like transactions. 
 4. Amendment of Loan Agreement (Section 14.1 Regarding “Permitted Investments”). Clause (f) of
the definition of “Permitted Investments” contained in Section 14.1 of the Loan Agreement that now reads as follows: 

“(f) Investments of Subsidiaries in or to other Subsidiaries or Borrower and Investments by Borrower in Subsidiaries not to exceed Five
Hundred Thousand Dollars ($500,000) in the aggregate in any fiscal year, provided that no new such Investment by Borrower in any Subsidiary may be made if a Default or an Event of Default is then occurring or would otherwise arise upon the making
thereof.” 
 is hereby amended, effective as of the date hereof, to read as follows: 

“(f) Investments of Subsidiaries in or to other Subsidiaries or Borrower and Investments by Borrower in Subsidiaries not to exceed Five
Million Dollars ($5,000,000) in the aggregate in any fiscal year, provided that no new such Investment by Borrower in any Subsidiary may be made if a 

 

 2 

 
Default or an Event of Default is then occurring or would otherwise arise upon the making thereof.” 

5. Limitations. 
 5.1 The agreements
set forth in this Consent are effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of any Loan
Document, or (b) otherwise prejudice any right or remedy which Bank may now have or may have in the future under or in connection with any Loan Document. 

5.2 This Consent shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations,
warranties, covenants and agreements set forth in the Loan Documents, except as herein amended, are hereby ratified and confirmed and shall remain in full force and effect. 

6. Bank Expenses. Borrower agrees to reimburse Bank for all its reasonable costs and expenses (including reasonable attorneys’ fees) incurred in
connection with this Consent. Bank is authorized to charge said fees, costs and expenses to Borrower’s loan account or any of Borrower’s deposit accounts maintained with Bank. 

7. Counterparts. This Consent may be executed in any number of counterparts and all of such counterparts taken together shall be deemed to constitute one
and the same instrument. 
  

 3 

 IN WITNESS WHEREOF, the parties hereto have caused
this Consent to be duly executed and delivered as of the date first written above. 
  

									
	BANK	 		 	BORROWER
			
	 SILICON VALLEY BANK
	 		 	 MOTRICITY, INC.

					
		 		 		 		 	
	By:	 	/s/ Jay Wefel	 		 	By:	 	/s/ Allyn P. Hebner
		 	 	 		 		 	 
	Name:	 	 Jay Wefel
	 		 	Name:	 	Allyn P. Hebner
		 	 	 		 		 	 
	Title:	 	 Relationship Manager
	 		 	Title:	 	Chief Financial Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00174-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00174-of-00352.parquet"}]]